Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orismilast for the treatment of moderate to severe ulcerative colitis
2022-502763-37-02Phase 2Completed
- Sponsor
- Copenhagen University Hospital - Hvidovre
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of orismilast in autoimmune colitis, sponsored by Copenhagen University Hospital - Hvidovre. Primary endpoint: Clinical remission on Total Mayo score at Week 12. Started Jun 2023; status: completed.
02
Drugs
orismilast
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-502763-37-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502763-37-02.